Therapy News and Research

RSS

Dutasteride may help reduce risk of developing prostate cancer, say researchers

A drug already used to shrink benign, enlarged prostates could also help to reduce the risk of developing prostate cancer, according to researchers in the US.

8 Apr 2010

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

8 Apr 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

8 Apr 2010

Oraya Therapeutics' IRay stereotactic radiotherapy system granted European CE Mark approval

Oraya Therapeutics, Inc. announces today that a leading European notified body has granted approval to designate the CE mark to Oraya's IRayTM stereotactic radiotherapy system. Under development since 2007, the IRay is designed specifically to treat diseases of the eye, and the technology enables precise delivery of low energy X-rays for the treatment of wet age-related macular degeneration (AMD).

8 Apr 2010

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals, Inc. today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX™ orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.

8 Apr 2010

Data illustrates methods for improving adherence to medication, lowering prescription drug costs

CVS Caremark presented data at the 22nd Annual Meeting of the Academy of Managed Care Pharmacy that illustrate successful methods for improving adherence to medication and lowering prescription drug costs. The company showed results from three studies which demonstrated the positive impact of various tools available to pharmacy benefit managers – including automated telephonic messaging, fax alerts to physicians about gaps in care, and strategic co-pay waivers for generic medications.

8 Apr 2010

BIOTRONIK receives European approval for new ProMRI Pacing Systems

BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, announced today the European approval of its new ProMRI Pacing Systems — Evia pacemaker series and Safio S pacing leads — providing European patients the first portfolio of bradycardia systems that are compatible with Magnetic Resonance Imaging (MRI) scans under specific conditions.

8 Apr 2010

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

7 Apr 2010

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.

7 Apr 2010

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

MAP Pharmaceuticals, Inc. today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia.

7 Apr 2010

Concerns over safety and effectiveness of "natural" treatments for treating anxiety

In a broad-based review of studies focused on drugs that treat anxiety, a Saint Louis University doctor found no evidence supporting the use of so-called "natural" treatments in combating the effects of anxiety.

7 Apr 2010

Investment report featuring Antares Pharma from BeaconEquity.com

BeaconEquity.com announces an investment report featuring medical instruments company Antares Pharma Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

7 Apr 2010

Mobile compression device effective in preventing blood clots after hip replacement surgery

A mobile compression device is as effective as medication at preventing the formation of blood clots after hip replacement surgery but provides greater patient safety, according to a study in the March issue of the Journal of Bone & Joint Surgery.

7 Apr 2010

New seminar series "Physical Care of Duchenne" unveiled

Duchenne Therapy Network today unveiled a new seminar series called, "Physical Care of Duchenne." The course, which includes two separate sessions taught by Jennifer Wallace, PT, will be held at the Ayres Hotel in Costa Mesa.

7 Apr 2010

Therapeutic swing for autism-spectrum disorder sheds metallic particles directly into eyes of children

The presence of metallic foreign bodies in the eye is an uncommon injury in children, so much so that two children with autism presenting with this injury led to detective work by two physicians that found the common cause.

7 Apr 2010

Researchers commence Phase 2 research study to test CERE-110 for AD

Researchers at Banner Sun Health Research Institute are about to start the first Phase 2 research study to test a gene transfer agent for Alzheimer's disease. AD is a degenerative and ultimately fatal disorder affecting as many as five million Americans and that number is expected to soar to more than 11 million by 2040.

7 Apr 2010

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., has jointly awarded a two-year, $200,000 grant to Dr. Joel Chamberlain, a research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool for facioscapulohumeral muscular dystrophy.

7 Apr 2010

Infusion and injection therapy Medicare defraud scheme: Detroit-area resident pleads guilty

A Detroit-area resident pleaded guilty today for her role in an infusion and injection therapy scheme to defraud Medicare, announced the Departments of Justice and Health and Human Services (HHS).

7 Apr 2010

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.

7 Apr 2010

African-American women with advanced breast cancer have poorer survival rates

African-American women have poorer survival rates than their white and Hispanic counterparts regardless of whether they receive radiation therapy following lumpectomy or mastectomy, UC Davis researchers have found.

7 Apr 2010

Therapy News and Research

Dutasteride may help reduce risk of developing prostate cancer, say researchers

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

Oraya Therapeutics' IRay stereotactic radiotherapy system granted European CE Mark approval

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

Data illustrates methods for improving adherence to medication, lowering prescription drug costs

BIOTRONIK receives European approval for new ProMRI Pacing Systems

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

Concerns over safety and effectiveness of "natural" treatments for treating anxiety

Investment report featuring Antares Pharma from BeaconEquity.com

Mobile compression device effective in preventing blood clots after hip replacement surgery

New seminar series "Physical Care of Duchenne" unveiled

Therapeutic swing for autism-spectrum disorder sheds metallic particles directly into eyes of children

Researchers commence Phase 2 research study to test CERE-110 for AD

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

Infusion and injection therapy Medicare defraud scheme: Detroit-area resident pleads guilty

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

African-American women with advanced breast cancer have poorer survival rates

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News